The phesgo market research report is one of a series of new reports that provides phesgo market statistics, including the phesgo industry global market size, regional shares, competitors with the phesgo market share, detailed phesgo market segments, market trends, and opportunities, and any further data you may need to thrive in the phesgo industry. This phesgo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the expanding biologics sector, growth in healthcare infrastructure, rising use of combination therapies, growing preference for targeted therapies, rising focus on patient-centered care, and increasing focus on subcutaneous biologics. Major trends in the forecast period include advancements in cancer immunotherapy, innovations in cancer treatment, technological advancements in drug delivery, advances in HER2 testing, and integration with digital health platforms.
The growing incidence of breast cancer is expected to drive the expansion of the phesgo market. Breast cancer, which originates in the cells of the breast - typically in the milk ducts or lobules - can spread to other parts of the body. The rising incidence of the disease is linked to factors such as an aging population, genetic predispositions, lifestyle changes, environmental factors, and hormonal influences. Phesgo provides breast cancer patients with a fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work together to block the HER2 protein responsible for tumor growth and progression. This combination reduces administration time and enhances the overall treatment experience. For example, according to the American Cancer Society, the number of new breast cancer cases in the U.S. increased from 300,590 in 2023 to 313,510 in 2024. As a result, the growing incidence of breast cancer is driving the market for phesgo.
The rising demand for personalized medicine is expected to fuel the growth of the phesgo market. Personalized medicine involves tailoring treatment plans to individual patients based on their genetic profile, lifestyle, and environmental factors, ensuring more effective and targeted therapies. The demand for such treatments is growing due to advances in genomics, which enable more precise therapies that improve outcomes and minimize side effects. Phesgo supports personalized medicine by combining pertuzumab and trastuzumab into a single subcutaneous injection, which targets the HER2 protein in HER2-positive breast cancer patients. This streamlined delivery method aligns with the needs of individual patients for precision care. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA had approved 16 new personalized treatments for rare diseases, including seven cancer drugs, a notable increase from six in 2022. Therefore, the increasing demand for personalized medicine is contributing to the growth of the phesgo market.
A significant trend in the phesgo market is the introduction of innovative therapies such as monoclonal antibody combination treatments, which aim to enhance efficacy and improve patient outcomes in oncology. Monoclonal antibody combination therapy involves using two or more antibodies together to target different aspects of a disease, often improving effectiveness and overcoming resistance mechanisms. In November 2023, Chugai Pharmaceutical Co. Ltd. launched Phesgo combination for Subcutaneous Injection MA, IN. This combination injectable medication includes pertuzumab and trastuzumab, two monoclonal antibodies, along with hyaluronidase alfa. It is used to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, offering a convenient subcutaneous administration option instead of the traditional intravenous infusion.
The key players in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.
North America was the largest region in the phesgo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phesgo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the phesgo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Phesgo is a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase for subcutaneous injection. It is used to treat HER2-positive breast cancer in both early and metastatic stages, typically in combination with chemotherapy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Phesgo are early-stage breast cancer and metastatic breast cancer. Early breast cancer, diagnosed at stages 0, I, or II, is treated with Phesgo to lower the risk of recurrence in HER2-positive cases. Phesgo is available in different formulations, including subcutaneous injection and intravenous infusion. It is distributed through various channels such as direct sales, online pharmacies, and wholesale distributors, and is utilized by a range of end users, including hospitals, oncology clinics, and home healthcare settings.
The phesgo market consists of sales of complementary chemotherapy agents, diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the expanding biologics sector, growth in healthcare infrastructure, rising use of combination therapies, growing preference for targeted therapies, rising focus on patient-centered care, and increasing focus on subcutaneous biologics. Major trends in the forecast period include advancements in cancer immunotherapy, innovations in cancer treatment, technological advancements in drug delivery, advances in HER2 testing, and integration with digital health platforms.
The growing incidence of breast cancer is expected to drive the expansion of the phesgo market. Breast cancer, which originates in the cells of the breast - typically in the milk ducts or lobules - can spread to other parts of the body. The rising incidence of the disease is linked to factors such as an aging population, genetic predispositions, lifestyle changes, environmental factors, and hormonal influences. Phesgo provides breast cancer patients with a fixed-dose combination of pertuzumab and trastuzumab, two targeted therapies that work together to block the HER2 protein responsible for tumor growth and progression. This combination reduces administration time and enhances the overall treatment experience. For example, according to the American Cancer Society, the number of new breast cancer cases in the U.S. increased from 300,590 in 2023 to 313,510 in 2024. As a result, the growing incidence of breast cancer is driving the market for phesgo.
The rising demand for personalized medicine is expected to fuel the growth of the phesgo market. Personalized medicine involves tailoring treatment plans to individual patients based on their genetic profile, lifestyle, and environmental factors, ensuring more effective and targeted therapies. The demand for such treatments is growing due to advances in genomics, which enable more precise therapies that improve outcomes and minimize side effects. Phesgo supports personalized medicine by combining pertuzumab and trastuzumab into a single subcutaneous injection, which targets the HER2 protein in HER2-positive breast cancer patients. This streamlined delivery method aligns with the needs of individual patients for precision care. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA had approved 16 new personalized treatments for rare diseases, including seven cancer drugs, a notable increase from six in 2022. Therefore, the increasing demand for personalized medicine is contributing to the growth of the phesgo market.
A significant trend in the phesgo market is the introduction of innovative therapies such as monoclonal antibody combination treatments, which aim to enhance efficacy and improve patient outcomes in oncology. Monoclonal antibody combination therapy involves using two or more antibodies together to target different aspects of a disease, often improving effectiveness and overcoming resistance mechanisms. In November 2023, Chugai Pharmaceutical Co. Ltd. launched Phesgo combination for Subcutaneous Injection MA, IN. This combination injectable medication includes pertuzumab and trastuzumab, two monoclonal antibodies, along with hyaluronidase alfa. It is used to treat HER2-positive breast cancer and advanced HER2-positive colorectal cancer, offering a convenient subcutaneous administration option instead of the traditional intravenous infusion.
The key players in the phesgo market are F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd.
North America was the largest region in the phesgo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phesgo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the phesgo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Phesgo is a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase for subcutaneous injection. It is used to treat HER2-positive breast cancer in both early and metastatic stages, typically in combination with chemotherapy.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Phesgo are early-stage breast cancer and metastatic breast cancer. Early breast cancer, diagnosed at stages 0, I, or II, is treated with Phesgo to lower the risk of recurrence in HER2-positive cases. Phesgo is available in different formulations, including subcutaneous injection and intravenous infusion. It is distributed through various channels such as direct sales, online pharmacies, and wholesale distributors, and is utilized by a range of end users, including hospitals, oncology clinics, and home healthcare settings.
The phesgo market consists of sales of complementary chemotherapy agents, diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Phesgo Market Characteristics4. Phesgo Market Trends And Strategies5. Phesgo Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Phesgo Pricing Analysis & Forecasts30. Global Phesgo Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Phesgo Market32. Recent Developments In The Phesgo Market
3. Phesgo Market Biologic Drug Characteristics
6. Global Phesgo Growth Analysis And Strategic Analysis Framework
8. Phesgo Market Segmentation
9. Global Phesgo Epidemiology Of Clinical Indications
10. Phesgo Market Regional And Country Analysis
11. Asia-Pacific Phesgo Market
12. China Phesgo Market
13. India Phesgo Market
14. Japan Phesgo Market
15. Australia Phesgo Market
16. South Korea Phesgo Market
17. Western Europe Phesgo Market
18. UK Phesgo Market
19. Germany Phesgo Market
20. France Phesgo Market
21. Eastern Europe Phesgo Market
22. North America Phesgo Market
23. USA Phesgo Market
24. Canada Phesgo Market
25. South America Phesgo Market
26. Middle East Phesgo Market
27. Africa Phesgo Market
28. Phesgo Market Competitive Landscape And Company Profiles
29. Global Phesgo Market Pipeline Analysis
33. Phesgo Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Phesgo Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on phesgo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for phesgo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phesgo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Early Breast Cancer; Metastatic Breast Cancer2) By Formulation: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Direct Sales; Online Pharmacies; Wholesale Distributors
4) By End User: Hospitals; Oncology Clinics; Home Healthcare
Key Companies Profiled: F. Hoffmann-La Roche AG; Chugai Pharmaceutical Co. Ltd.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche AG
- Chugai Pharmaceutical Co. Ltd.
